Sofosbuvir and daclatasvir combination therapy for current hepatitis C virus genotype 4 achieves SVR: a case report of HCV genotype 4 from the Amazon
Rev. Soc. Bras. Med. Trop
; 50(6): 861-863, Nov.-Dec. 2017. tab
Article
in En
| LILACS
| ID: biblio-897030
Responsible library:
BR1.1
ABSTRACT
Abstract Hepatitis C is a worldwide endemic disease. However, hepatitis C virus genotype 4 (HCV GT-4) has rarely been reported in Brazil. HCV GT-4 demonstrates high sustained virological response (SVR). Here, we report the case of a 62-year-old HCV GT-4 positive woman complaining of a headache, nausea, and arthralgia. The patient was treated according to the protocol for genotype 4 (12 weeks administration of 400mg sofosbuvir and 60mg daclatasvir daily) and achieved SVR. Although this is not an Amazonas autochthonous case, the presence of genotype 4 is rarely reported in the region.
Key words
Full text:
1
Index:
LILACS
Main subject:
Antiviral Agents
/
Hepatitis C, Chronic
/
Sofosbuvir
/
Imidazoles
Limits:
Female
/
Humans
Language:
En
Journal:
Rev. Soc. Bras. Med. Trop
Journal subject:
MEDICINA TROPICAL
Year:
2017
Type:
Article